Formation Bio has unveiled a $600 million fund aimed at expanding its drug development pipeline, utilizing AI to accelerate clinical progress.

Formation Bio welcomes Anirvan Ghosh, a seasoned expert in drug development, as its new SVP, Head of Translational Sciences, to strengthen its pipeline.

Formation Bio has appointed Michael Ehlers as Chief Scientific Officer to lead R&D efforts. His extensive experience will enhance the company’s drug development capabilities.

Lynk Pharmaceuticals celebrates a major achievement as BLKR201 enters the Phase 1 trial phase, aiming to treat autoimmune and inflammatory diseases with a cutting-edge TYK2 inhibitor.

Formation Bio expands its portfolio with the acquisition of an innovative oral treatment for autoimmune diseases, enhancing patient care options.

Lynk Pharmaceuticals partners with Formation Bio to advance LNK01006, a selective TYK2 inhibitor, into clinical testing and development.

Formation Bio has secured global rights to LNK01006, a promising CNS-penetrant TYK2 inhibitor from Lynk Pharmaceuticals, enhancing their immunology portfolio.

Formation Bio has appointed top executives from leading biotech and pharma companies to strengthen its AI-driven drug development mission. These appointments are set to transform the company's operational framework to enhance patient outcomes.

Formation Bio has secured a license for IMIDomics' first-in-class anti-CD226 monoclonal antibody, targeting autoimmune diseases like ulcerative colitis, promising a new treatment avenue.

Formation Bio has launched its inaugural Entrepreneurs in Residence program, enlisting top experts to enhance drug development and business growth strategies.